Tactical Therapeutics
Media Center
Press Releases
AACR meeting April 29, 2025
Tactical Therapeutics presents Long-term Late Breaking Data of CTO Treatments for Glioblastoma at AACR meeting April 29, 2025
AACR meeting April 29, 2025
Read MoreMedInvest Oncology Investor Conference
Tactical Therapeutics, Inc., Developer of CTO Treatments for Glioblastoma, Selected to Present at MedInvest Oncology Investor Conference December 14-15 in New York
MedInvest Oncology Investor Conference
Read MoreCavendish Global Health Impact Forum
Tactical Therapeutics, Inc., Selected to Present at Cavendish Global Health Impact Forum
Cavendish Global Health Impact Forum
Read MoreBioWorld’s Partner in Focus
BioWorld’s Partner in Focus: Tactical Therapeutics
BioWorld’s Partner in Focus
ViewPhase 1B Trials
Tactical Therapeutics Announces the Publication of Promising Results of Phase 1B Trials of Carboxyamidotriaxole Orate (CTO) in Glioblastomas
Phase 1B Trials
ViewBioNJ Partnering Conference
Tactical Therapeutics, Inc. Presented at the Virtual BioNJ Partnering Conference, October 6-7, 2020
BioNJ Partnering Conference
WatchPublications
Cancer Therapy Vol 5, Page 437
Gary J. Grover, Jane Kelly, George Moore, Henry Jacoby, Rashida A. Karmali, Gregory S. Gorman, 2007, 5: 437-442
Cancer Therapy Vol 5, Page 437
Read MoreCancer Therapy Vol 8, page 71
Karmali R., Maxuitenko, Y., Gorman, G., Page, J.G, Cancer Therapy. 2011;8:71-80. Epub 20 December 2011
Cancer Therapy Vol 8, page 71
Read MoreJournal of Cancer Therapy, 2013, 4, 857-871
Karmali, R.A., Maxuitenko, Y., Gorman, G, J. Cancer Therapy, 2013, 4: 857-871
Journal of Cancer Therapy, 2013, 4, 857-871
Read MoreJournal of Cancer Therapy, 2015, 6, 322-333
Taylor M.H., Sandler A., Urba W.J., Omuro A.M.P., Gorman G.S., Karmali R.A., JCT. 2015; 6:322-333
Journal of Cancer Therapy, 2015, 6, 322-333
Read MoreJournal Of Clinical Oncology
Omuro A., Karmali, R.A., Pentsova, E., J. Clin. Once. (2018), 36:1702-1709; JCO 2017; 76:9992
Journal Of Clinical Oncology
ViewAbstracts
Kaley, T., et al.
Carboxyamidotriazole orotate (CTO) with temozolomide (TMZ) for recurrent high-grade gliomas (rHGG) and in combination with TMZ/RT->TMZ in newly diagnosed glioblastoma (ndGBM): Long term follow-up of phase IB trial.
Kaley, T., et al.
ListenOmuro, A. M. P., et. al.
Phase IB trial of carboxyamidotriazole orotate (CTO) and radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in newly diagnosed glioblastoma (GBM) . J.Clin Oncol 34, 2016 (suppl; Abstract 2060).
Omuro, A. M. P., et. al.
ViewLin, X., et. al.
Phase IB trial of carboxyamidotriazole orotate (CTO) combined with temozolomide (TMZ) for recurrent glioblastoma (GBM) and other malignant gliomas (MG) J. Clin Oncol 34, 2016 (suppl; Abstract 2064).
Lin, X., et. al.
ViewThomas, A., et al.
Phase IB trial of CTO and radiotherapy with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma. J. Clin Oncol 33, 2015 (suppl; Abstract 2062)
Thomas, A., et al.
Read MoreOmuro, A. M. P., et. Al.
Phase IB Trial of Carboxyamidotriazole Orotate (CTO) and Temozolomide for Recurrent Malignant Glioma (MG): A Novel Mechanism for Modulation of Multiple Oncogenic pathways J. Clin Oncol 32, 2014 (suppl; Abstract 2071)
Omuro, A. M. P., et. Al.
ViewMagge, R., et al.
Dynamic contrast-enhanced magnetic resonance perfusion weighted imaging (DCE-MRI) and diffusion weighted imaging (DWI) for pharmacodynamic evaluation of CTO and temozolomide in malignant glioma. Society of Neuro-oncology, 2014. Abstract.
Magge, R., et al.
ViewSandler, A., et. Al.
A Phase I Study of Carboxyamidotriazole Orotate (CTO) in Treatment of Advanced Solid Tumors. J. Clin Oncol xx, 2013 (suppl; Abstract 2518).
Sandler, A., et. Al.
ViewKarmali R, Miele, G., editor
Pharmacodynamic Transcriptional markers of carboxyamidotriazole orotate (CTO) exposure in anagen hair. Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 19-23 October, Abs. 367; Boston MA.